About TSO3
Company Overview
TSO3 was founded in June of 1998, supported by a patented and unique technology for the sterilization of medical devices. This process uses ozone as the sterilizing agent and has been designed to allow the sterilization of heat and moisture-sensitive medical devices in healthcare settings.
The STERIZONE® Sterilization Process sterilizes large loads of medical devices quickly, cost-effectively, safely and in an eco-friendly way. This is in contrast to traditional gaseous low temperature sterilization methods which rely on toxic chemistry and require lengthy sterilization cycle times, or newer competitive oxidizing sterilizers which are costly to operate and limited in capability due to their load restrictions.
TSO3’s first product, the STERIZONE® 125L Sterilizer has received clearance for commercialization from both Health Canada and the United States Food and Drug Administration (FDA).
A new Vision
Starting in late 2008, TSO3 made a series of changes in its leadership that would introduce new people and skills to build on what had already been started. TSO3’s Board of Directors appointed Mr. R.M. (Ric) Rumble to the position of CEO. Mr. Rumble then selected Mr. Robert F. Mosher, as Global Marketing Vice-President.
The Plan
At TSO3’s Annual General Meeting of the Shareholders held on April 30, 2009, the new management team presented a three year plan, consistent with the company’s new vision. This vision is: “To Create the Improved Standard in Healthcare Sterilization”.
The plan described the following core objectives:
- Improve product utility through increased compatibility (gentler cycles on device materials) and cycle speed.
- Increase market opportunities via expansion outside North America.
- Develop relationships leading to a strategic channel partner.
To see steps towards the execution of our plan, visit our news room.
To learn more about the STERIZONE® 125L Sterilizer, visit our products section.